Fusion Pharmaceuticals to Participate at the Cowen 42nd Annual Health Care Conference
Fusion Pharmaceuticals (Nasdaq: FUSN) announced its participation in the "Novel Oncology Targets" panel at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 12:50 p.m. ET. CEO John Valliant, Ph.D. will represent the company. A webcast of the event will be available on their website, with a replay accessible for about 30 days. Fusion is focused on developing next-generation radiopharmaceuticals as precision medicines, with ongoing clinical trials and collaborations with major partners like AstraZeneca and Merck.
- None.
- None.
HAMILTON, ON and BOSTON, Feb. 28, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Novel Oncology Targets" panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 12:50 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.
A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for approximately 30 days following the panel discussion.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.
Fusion Contact: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, cray@fusionpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-participate-at-the-cowen-42nd-annual-health-care-conference-301491963.html
SOURCE Fusion Pharmaceuticals Inc.
FAQ
What event will Fusion Pharmaceuticals attend on March 7, 2022?
Who will represent Fusion Pharmaceuticals at the Cowen Conference?
Where can I watch the Fusion Pharmaceuticals conference presentation?
What is Fusion Pharmaceuticals' focus in oncology?
What are Fusion Pharmaceuticals' lead programs?
